News Industry News STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes May 25, 2017
News Conference News EuroPCR 2017 BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI Michael O'Riordan May 18, 2017
News Industry News Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience May 16, 2017
News Conference News EuroPCR 2017 DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit Michael O'Riordan May 16, 2017
News Conference News EuroPCR 2017 EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40 Shelley Wood May 12, 2017
News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
Presentation 10-Year Clinical Outcome After Randomization to Sirolimus- or Paclitaxel-Eluting Coronary stents February 13, 2017
Presentation JIM 2017 Preliminary Clinical Results with the New Sirolimus Drug Coated Balloon Presenter: Bernardo Cortese February 10, 2017
News Daily News 10-Year Follow-up of Early DES Shows Steady Risk of Late Events L.A. McKeown February 08, 2017
News Daily News After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD Michael O'Riordan December 14, 2016
News Industry News Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan November 29, 2016
News Conference News TCT 2016 Novel SES Fails to Match Xience EES for Chronic Total Occlusions Yael L. Maxwell November 08, 2016
News Industry News Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016 November 03, 2016
News Industry News TCT 2016 Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions November 02, 2016
Presentation TCT 2016 PRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients With Coronary Artery Chronic Total Occlusions Presenter: Gary S. Mintz, Robert-Jan van Geuns, Koen Teeuwen November 02, 2016
News Conference News TCT 2016 New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts Yael L. Maxwell October 31, 2016
News Industry News TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies October 31, 2016
Presentation TCT 2016 FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Bo Xu October 31, 2016
Presentation TCT 2016 FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Antonio Colombo October 31, 2016
Presentation TCT 2016 MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Ashok Seth October 31, 2016